Track Aardvark Therapeutics, Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aardvark Therapeutics, Inc. Common Stock AARD · Stock Open Aardvark Therapeutics, Inc. Common Stock in new tab

1.33 USD
EPS
-3.21
P/B
0.39
ROE
-66.02
Target Price
4.57 USD
Loading chart...
Key Metrics
Earnings dateMarch 22, 2027
EPS-3.21
Book Value3.42
Price to Book0.39
Debt/Equity0.91
% Insiders15.771%
Estimates
Forward P/E-0.59
Forward EPS-2.30
Target Mean Price4.57

DCF valuation

Model fair value for Aardvark Therapeutics, Inc. Common Stock (AARD)
Result
Sign in to run the valuation for AARD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Buy · mean target 4.57 USD (low 1.50, high 10.00) · as of 10 Nov 2026
Low 1.50
Mean 4.57
High 10.00
Price 1.33
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Aardvark Therapeutics, Inc. Common Stock Logo Aardvark Therapeutics, Inc. Common Stock Analysis (AARD)

US Healthcare Official Website Stock

Is Aardvark Therapeutics, Inc. Common Stock a good investment? Aardvark Therapeutics, Inc. Common Stock (AARD) is currently trading at 1.33 USD. Market analysts have a consensus price target of 4.57 USD. This suggests a potential upside from current levels.

Earnings Schedule: Aardvark Therapeutics, Inc. Common Stock is expected to release its next earnings report on March 22, 2027. The market consensus estimate for Forward EPS is -2.30.

Investor FAQ

Does Aardvark Therapeutics, Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aardvark Therapeutics, Inc. Common Stock?

Aardvark Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 22, 2027. The company currently has a trailing EPS of -3.21.

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Exchange Ticker
NASDAQ AARD
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion